Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug Classification

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,075 result(s) found for: Drug Classification. Displaying page 1 of 54.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-005220-26 Sponsor Protocol Number: ACE-LY-308 Start Date*: 2017-05-16
    Sponsor Name:Acerta Pharma BV
    Full Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Un...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) DE (Ongoing) BE (Ongoing) ES (Ongoing) CZ (Ongoing) GR (Ongoing) PL (Ongoing) FR (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001284-24 Sponsor Protocol Number: BGB-3111-214 Start Date*: 2019-04-01
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma
    Medical condition: Relapsed or Refractory Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-002730-16 Sponsor Protocol Number: GLS27-005 Start Date*: 2021-10-25
    Sponsor Name:GeneOne Life Science Inc.
    Full Title: Safety, Tolerability, Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis caused by SARS-CoV-2 Infection
    Medical condition: Patients with SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002579-33 Sponsor Protocol Number: EE-301 Start Date*: 2020-03-26
    Sponsor Name:Phathom Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophag...
    Medical condition: Erosive Esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10063657 Erosive esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-002724-17 Sponsor Protocol Number: 02-NDOL-006 Start Date*: 2005-04-19
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: Efficacy of Neodolpasse™ in the treatment of postoperative pain: Morphine sparing effect during the first 24 hours postoperatively after unilateral total hip arthroplasty.
    Medical condition: Patients with ASA classification I-III, female or male between 18 and 85 years of age, undergoing primary cementless unilateral total hip arthroplasty
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000619-17 Sponsor Protocol Number: NAXIVA1.0 Start Date*: 2017-08-02
    Sponsor Name:Common Services Agency (CSA)
    Full Title: Phase II neoadjuvant study of Axitinib for reducing extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion.
    Medical condition: Venous tumour thrombus in clear cell renal cell cancer with venous invasion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-000204-14 Sponsor Protocol Number: GS-US-428-4194 Start Date*: 2019-09-11
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis
    Medical condition: Primary Sclerosing Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DK (Prematurely Ended) FR (Completed) ES (Restarted) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004958-14 Sponsor Protocol Number: E2090-S082-409 Start Date*: 2017-04-24
    Sponsor Name:Eisai Korea Inc.
    Full Title: A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
    Medical condition: Epilepsy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-002089-11 Sponsor Protocol Number: CMBG453B12301 Start Date*: 2020-06-23
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodyspla...
    Medical condition: adult subjects with intermediate, high or very high risk (per IPSS-R prognostic risk categories) myelodysplastic syndrome or with Chronic Myelomonocytic Leukemia - 2 (CMML-2)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Ongoing) CZ (Ongoing) BE (Ongoing) IT (Ongoing) ES (Ongoing) AT (Completed) GB (GB - no longer in EU/EEA) PT (Temporarily Halted) FI (Completed) LT (Ongoing) NL (Ongoing) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000736-21 Sponsor Protocol Number: HLX01-FL03 Start Date*: 2020-07-02
    Sponsor Name:Shanghai Henlius Biotech Inc.
    Full Title: A Phase 3 Multi-Centre, Randomised, Double-Blind, Parallel-Arm Study to Evaluate the Efficacy and Safety of HLX01 Versus Rituximab (Mabthera®) as First Line Treatment in Patients With Low Tumour Bu...
    Medical condition: Low tumour burden follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003932-40 Sponsor Protocol Number: 1138.11 Start Date*: 2009-03-26
    Sponsor Name:Boerhinger Ingelheim Pharma GmbH & Co.KG
    Full Title: A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 720mg/day orally, in male and female patients suff...
    Medical condition: chronic venous insufficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066682 Chronic venous insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001361-33 Sponsor Protocol Number: CYP-CLI-P2-01 Start Date*: 2020-07-27
    Sponsor Name:Cynata Therapeutics Limited
    Full Title: A Randomised, Double-blind, Placebo-controlled Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of CYP-002 in Adults with Critical Limb Ischaemia who are Unsuitable for Revascular...
    Medical condition: Critical Limb Ischaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10058069 Critical limb ischemia LLT
    21.1 100000004866 10058072 Critical limb ischaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-009836-54 Sponsor Protocol Number: CC-5013-CLL-009 Start Date*: 2009-11-20
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY OF THE SAFETY AND EFFICACY OF DIFFERENT LENALIDOMIDE (REVLIMID®) DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL...
    Medical condition: For the treatment of patients with B-cell chronic lymphocytic leukemia who have failed at least 1 prior therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) SE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004549-23 Sponsor Protocol Number: TV48125-CNS-30049 Start Date*: 2016-11-24
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for...
    Medical condition: Chronic Migraine
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10066636 Chronic migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) FI (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000455-16 Sponsor Protocol Number: CYT/Heparin_01/11 Start Date*: 2011-05-05
    Sponsor Name:CYATHUS EXQUIRERE PharmaforschungsGmbH
    Full Title: Efficacy and local tolerability of topically applied heparin (Heparin 2,400 IU/ml Cutaneous Spray) on the suitability of newly constructed primary arteriovenous Fistulas in haemodialysed patients
    Medical condition: This placebo-controlled, randomized and double-blinded pilot study aims to confirm the previous study performed by Stuard et al. (2010) by proving clinically efficacy and local tolerability of topi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006194-26 Sponsor Protocol Number: EC11-185 Start Date*: 2012-06-29
    Sponsor Name:JOSE LUIS MONTERO ALVAREZ
    Full Title: A phase IV, multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of Sorafenib in patients with hepatocellular carcinoma after radiological progression
    Medical condition: Advanced stage hepatocellular carcinoma (stage C of BCLC classification)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003954-15 Sponsor Protocol Number: BIOS-14-002 Start Date*: 2015-05-06
    Sponsor Name:Ethicon, Inc.
    Full Title: A single blinded, randomized, controlled study to evaluate the safety and effectiveness of EVICEL® Fibrin sealant (Human) compared to a Hydrogel sealant as an adjunct to sutured dural repair
    Medical condition: Cerebrospinal fluid leakage in posterior fossa or supratentorial procedures (craniectomy or craniotomy) during neurosurgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003581-20 Sponsor Protocol Number: ALPHA Start Date*: 2023-03-21
    Sponsor Name:Medical University Vienna
    Full Title: Albendazole pharmacokinetics in plasma, intra-cystic fluid, and cystic tissue of human cystic and alveolar echinococcosis
    Medical condition: Albendazole is an orally administered broad-spectrum anthelmintic Drug used in treatment of human alveolar and cystic echinococcosis. To date, data on albendazole and tissue pharmacokinetics are li...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013404-32 Sponsor Protocol Number: GFM-clo-08 Start Date*: 2009-07-23
    Sponsor Name:Groupe Francophone des Myélodysplasies (GFM)
    Full Title: A Phase I/II Multicenter Study of IV Clofarabine In Patients with High-Risk Myelodysplastic Syndrome who have failed Therapy with Azacitidine: the NIDEVOL study
    Medical condition: In Patients with High-Risk Myelodysplastic Syndrome who have failed Therapy with Azacitidine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005192-89 Sponsor Protocol Number: C1231001 Start Date*: 2015-04-21
    Sponsor Name:Hospira UK Ltd.
    Full Title: Post-Marketing Observational Cohort Study of Patients with Inflammatory Bowel Disease (IBD) Treated with CT-P13 in Usual Clinical Practice (CONNECT-IBD)
    Medical condition: Inflamatory Bowel Disease (IBD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10021973 Inflammatory bowel disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:19:41 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA